Pfizer Inc (NYSE:PFE) has a beta value of 0.54 and has seen 7.35 million shares traded in the recent trading session. The company, currently valued at $139.63B, closed the recent trade at $24.62 per share which meant it gained $0.08 on the day or 0.33% during that session. The PFE stock price is -28.11% off its 52-week high price of $31.54 and 0.57% above the 52-week low of $24.48. If we look at the company’s 10-day average daily trading volume, we find that it stood at 75.45 million shares traded. The 3-month trading volume is 45.47 million shares.
The consensus among analysts is that Pfizer Inc (PFE) is Buy stock at the moment, with a recommendation rating of 2.29. 1 analysts rate the stock as a Sell, while 1 rate it as Overweight. 7 out of 16 have rated it as a Hold, with 7 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is 0.72.
Pfizer Inc (NYSE:PFE) trade information
Sporting 0.33% in the green today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the PFE stock price touched $24.62 or saw a rise of 3.15%. Year-to-date, Pfizer Inc shares have moved -7.20%, while the 5-day performance has seen it change -2.34%. Over the past 30 days, the shares of Pfizer Inc (NYSE:PFE) have changed -4.39%. Short interest in the company has seen 99.17 million shares shorted with days to cover at 2.34.
Wall Street analysts have a consensus price target for the stock at $32, which means that the shares’ value could jump 23.06% from the levels at last check today. The projected low price target is $32.0 while the price target rests at a high of $33.0. In that case, then, we find that the latest price level in today’s session is -34.04% off the targeted high while a plunge would see the stock gain -29.98% from the levels at last check today.
Pfizer Inc (PFE) estimates and forecasts
The company’s shares have lost -14.93% over the past 6 months. Revenue growth from the last financial year stood is estimated to be -1.09%.
12 analysts offering their estimates for the company have set an average revenue estimate of 14.43B for the current quarter. 11 have an estimated revenue figure of 13.54B for the next ending quarter. Year-ago sales stood 14.88B and 13.28B respectively for this quarter and the next, and analysts expect sales will shrink by -3.04% for the current quarter and -1.09% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -13.25% over the past 5 years. Earnings growth for 2025 is a modest -4.91% while over the next 5 years, the company’s earnings are expected to decrease by -0.97%.
PFE Dividends
Pfizer Inc is expected to release its next earnings report on 2025-Feb-03 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue. The forward dividend is 1.69 at a share yield of 6.86%. The company’s dividend yield has gone up over the past 12 months, with a 5 Year Average Dividend Yield of 4.43%.
Pfizer Inc (NYSE:PFE)’s Major holders
Insiders own 0.06% of the company shares, while shares held by institutions stand at 67.52% with a share float percentage of 67.56%. Investors are also buoyed by the number of investors in a company, with Pfizer Inc having a total of 3678.0 institutions that hold shares in the company. The top two institutional holders are VANGUARD GROUP INC with over 511.4 million shares worth more than $14.31 billion. As of 2024-06-30, VANGUARD GROUP INC held 9.0402% of shares outstanding.
The other major institutional holder is BLACKROCK INC., with the holding of over 424.38 million shares as of 2024-06-30. The firm’s total holdings are worth over $11.87 billion and represent 7.4899% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard 500 Index Fund. As of Dec 31, 2024, the former fund manager holds about 3.13% shares in the company for having 177.62 shares of worth $4.38 billion while later fund manager owns 153.4 shares of worth $3.78 billion as of Dec 31, 2024, which makes it owner of about 2.70% of company’s outstanding stock.
